Liraglutide vs Retatrutide
Both Liraglutide and Retatrutide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
Liraglutide
Evidence A+Liraglutide (Saxenda / Victoza)
The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.
View full Liraglutide profile →Retatrutide
Evidence ARetatrutide (LY3437943)
Triple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.
View full Retatrutide profile →Side-by-Side
| Attribute | Liraglutide | Retatrutide |
|---|---|---|
| Evidence Grade | A+ | A |
| FDA Status | FDA-approved for weight management (Saxenda) and type 2 diabetes (Victoza) | Not FDA-approved — Phase 3 trials (TRIUMPH program) for obesity |
| Typical Dose | 0.6–3.0 mg daily (subcutaneous) | Trial range: 1–12 mg weekly (subcutaneous) |
| Clinics Indexed | 540 | 12 |
| Categories | weight-loss, metabolic | weight-loss, metabolic |
Key reported benefits — Liraglutide
- ✓Weight loss
- ✓Appetite suppression
- ✓Glycemic control
Key reported benefits — Retatrutide
- ✓Highest reported weight loss
- ✓Triple incretin/glucagon mechanism
- ✓Metabolic improvement
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.